Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other 1Gynecologic 1

Conditions

Polycystic Ovary Syndrome 1Ovarian Neoplasms 1Obesity 1

Interventions

pembrolizumab 1262Specimen Handling 924Magnetic Resonance Spectroscopy 829Carboplatin 821Cyclophosphamide 799Cisplatin 722Nivolumab 667Paclitaxel 627Radiotherapy 608Gemcitabine 570Biopsy 557Bevacizumab 478Dexamethasone 437fludarabine 407Docetaxel 377venetoclax 367Oxaliplatin 364Capecitabine 355Fluorouracil 355atezolizumab 350durvalumab 332Rituximab 329Drug Therapy 325Doxorubicin 316Radiosurgery 314Standard of Care 309Blood Specimen Collection 308Pemetrexed 304Ipilimumab 298Radiation 285

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
mirabegron × 1 year × Clear all
NCT03049462 2026-06-01

The Physiological Responses and Adaptation of Brown Adipose Tissue to Chronic Treatment With Beta3-Adrenergic Receptor Agonists

National Institutes of Health Clinical Center (CC)

Phase 1 Recruiting
100 enrolled
Other

Obesity, Polycystic Ovary Syndrome

NCT07261683 2025-12-19

Phase II Study of Weekly Paclitaxel/Nab-Paclitaxel, Pembrolizumab, and Mirabegron for Recurrent Ovarian Cancer

Obstetrics & Gynecology Hospital of Fudan University

Phase 2 Recruiting
20 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡